Loading
RO7269162 / Alzheimer's Disease · Phase 2 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 randomized controlled trial of RO7269162 versus placebo in participants at risk for or with prodromal Alzheimer's disease, powered to assess safety and amyloid biomarker change over 72 weeks. No results are reported in this registry record; the study is currently active but not recruiting.
Phase 2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Alzheimer's Disease; age from 60 Years; to 85 Years. Intervention: RO7269162. Compared with: Placebo — Placebo Comparator. n = 256. 46 sites across 9 countries.
This is a Phase 2 randomized controlled trial of RO7269162 versus placebo in participants at risk for or with prodromal Alzheimer's disease, powered to assess safety and amyloid biomarker change over 72 weeks. No results are reported in this registry record; the study is currently active but not recruiting.
No efficacy or safety results are reported in this registry record; the trial is ongoing. Primary outcomes are limited to safety events and amyloid biomarker change; clinical cognitive endpoints are not listed.
The source did not state who this applies to in practice.
This is an active Phase 2 trial registration with no results posted; the evidence base is the study design and planned endpoints only, not clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06402838). This is a study registration, not published results. Lead sponsor: Hoffmann-La Roche. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 256 participants (ACTUAL). Conditions: Alzheimer's Disease. Interventions: DRUG: RO7269162; DRUG: Placebo. Primary outcome measures: Incidence of adverse events (AEs) , up to week 72; Change from baseline in brain amyloid load, as measured by amyloid positron emission tomography ( PET) scan , Baseline to Week 72. Brief summary: This clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment. People can take part if they have a certain level of plaques (beta-amyloid) in the brain, shown by a positron emission tomography (PET) scan, a medical imaging technique in which tracers are injected to visualize specific pathological processes in the brain. People who take part in this clinical trial (participants) will be given RO7269162 OR placebo for up to about 1 and a half years. The clinical trial team will see them every 3 weeks in the first 3 months and then every 6 weeks until the end of the trial. These hospital visits will include checks to see how the participant responds to the treatment and any side effects they may have. The total time of participation in the clinical trial will be 90 weeks.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.